0001209191-20-011824.txt : 20200221 0001209191-20-011824.hdr.sgml : 20200221 20200221200236 ACCESSION NUMBER: 0001209191-20-011824 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200121 FILED AS OF DATE: 20200221 DATE AS OF CHANGE: 20200221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kent Jeff CENTRAL INDEX KEY: 0001769107 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-35238 FILM NUMBER: 20641801 MAIL ADDRESS: STREET 1: C/O HORIZON PHARMA PLC STREET 2: CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD CITY: DUBLIN STATE: L2 ZIP: 4 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Horizon Therapeutics Public Ltd Co CENTRAL INDEX KEY: 0001492426 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 BUSINESS PHONE: 011-353-1-772-2100 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 FORMER COMPANY: FORMER CONFORMED NAME: Horizon Pharma plc DATE OF NAME CHANGE: 20140919 FORMER COMPANY: FORMER CONFORMED NAME: HORIZON PHARMA, INC. DATE OF NAME CHANGE: 20100520 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2020-01-21 2020-01-23 0 0001492426 Horizon Therapeutics Public Ltd Co HZNP 0001769107 Kent Jeff C/O HORIZON THERAPEUTICS PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 4 IRELAND 0 1 0 0 See remarks Ordinary Shares 2020-01-21 4 A 0 3045 0.00 A 114712 D Ordinary Shares 2020-01-21 4 F 0 1349 38.25 D 113363 D Performance Restricted Stock Units (PSUs) 2020-01-21 4 A 0 6091 0.00 A Ordinary Shares 6091 6091 D On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. Each PSU represents a contingent right to receive one ordinary share of the Issuer. Officer Title: SVP, Head of Medical Affairs & Outcomes Research The share amounts set forth in the original Form 4 filing were incorrect. This amended report corrects and replaces the original Form 4 filing in its entirety. /s/ Miles W. McHugh, Attorney-in-Fact 2020-02-21